葛兰素史克总公司向中国人民的致歉声明

葛兰素史克总公司向中国人民的致歉声明

　　中国司法机关经过全面深入调查，依法认定葛兰素史克中国公司为谋取不正当利益，给予非国家工作人员财物，构成对非国家工作人员行贿罪。葛兰素史克总公司完全认同中国司法机关依法认定的事实和证据，服从中国司法机关的依法判决，并向中国患者、医生、医院和中国政府、全体中国人民深刻道歉，对于由此造成的损害，葛兰素史克总公司深感痛心和愧疚。对由于受到葛兰素史克中国公司非法调查而受到伤害的有关人员，葛兰素史克总公司也深表歉意。

　　葛兰素史克中国公司的违法行为同样严重违背了葛兰素史克总公司的规章制度，完全背离了总公司要求员工遵守的价值观和行为准则。这些行为未能及时被发现并被制止，葛兰素史克总公司深感遗憾。葛兰素史克总公司已经深刻反省，并从中吸取教训，采取了具体措施，全面整改葛兰素史克中国公司运营中存在的问题，尽一切努力，重新赢得中国人民的信任。

　　今天，葛兰素史克总公司进一步向中国政府和人民承诺，葛兰素史克中国公司将以实际行动在中国医药行业树立改革的样板：将坚持在中国持续投资，并一如既往地支持中国的科技发展；将针对流行于中国的疾病，进一步推进药物和疫苗的研发。葛兰素史克中国公司还将通过扩大生产、扩大药品价格下浮空间，让中国农村地区和城市一样，提高对葛兰素史克药品的可及性。

　　葛兰素史克总公司将以践行这一系列长远的发展战略，致力于促进中国人民的健康福祉，为中国经济社会发展积极贡献力量。

GSK plc Statement of Apology to the People of China

　　Following a comprehensive investigation by the Chinese judicial authorities, GSK China Investment Co. Ltd (GSKCI) has been identified according to Chinese law to have offered money or property to non-government personnel in order to obtain improper commercial gains, and has been found guilty of bribing non-government personnel. GSK plc fully accepts the facts and evidence of the investigation, and the verdict of the Chinese judicial authorities. Furthermore, GSK plc sincerely apologises to the Chinese patients, doctors and hospitals, and to the Chinese Government and the Chinese people. GSK plc deeply regrets the damage caused. GSK plc also apologises for the harm caused to individuals who were illegally investigated by GSKCI.

　　The illegal activities of GSKCI are a clear breach of GSK plc’s governance and compliance procedures; and are wholly contrary to the values and standards we expect from our employees. It is deeply disappointing that these issues were not identified and addressed. GSK plc has reflected deeply and learned from its mistakes, has taken steps to comprehensively rectify the issues identified at the operations of GSKCI, and must work hard to regain the trust of the Chinese people.

　　Today, GSK plc makes a further commitment to the Chinese government and people that GSKCI will take tangible actions to establish itself as a model for reform in China’s healthcare industry: by continuing to invest in China and supporting China's scientific development; and by further development of innovative new medicines and vaccines for diseases prevalent in China. GSKCI will also increase access to its products in both city and rural areas of China through greater expansion of production and through price flexibility.

　　This long-term development strategy of GSK plc will promote the future health and well-being of the Chinese people, and positively contribute to China’s economic and social development.

相关链接：